EAU 2014 - Poster: Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase 3 trials

STOCKHOLM, SWEDEN (UroToday.com) - Presented by Michael Stöckle,1 Thomas Flaig,2 Carsten H. Ohlmann,1 Howard I. Scher,3 Johann S. de Bono,4 Dana E. Rathkopf,3 Charles J. Ryan,5 Thian Kheoh,6 Jinhui Li,7 Mary B. Todd,8 Thomas W. Griffin,6 Arturo Molina,9 and Karim Fizazi10 at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden.

Abiraterone-EAU-Stockle-poster thumb

1Saarland University, Homburg/Saar, Germany; 2University of Colorado Cancer Center, University of Colorado School of Medicine, Aurora, CO, USA; 3Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA; 4The Institute of Cancer Research and The Royal Marsden Hospital, Sutton, UK; 5Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA; 6Janssen Research & Development, Los Angeles, CA, USA; 7Janssen Research & Development, Raritan, NJ, USA; 8Janssen Global Services, Raritan, NJ, USA; 9Janssen Research & Development, Menlo Park, CA, USA; 10Institut Gustave Roussy, University of Paris Sud, Villejuif, France

Click HERE to read an exclusive report by a UroToday medical writer